Medicine (May 2022)

Clinical impact of pretreatment albumin–globulin ratio in patients with colorectal cancer

  • Jian-Ying Ma, MD,
  • Gang Liu, MD,
  • Liang-Zhi Pan, MD,
  • Min Hu, MD,
  • Zhong-Zhong Zhu, MD,
  • Christine Pocha.

DOI
https://doi.org/10.1097/MD.0000000000029190
Journal volume & issue
Vol. 101, no. 20
p. e29190

Abstract

Read online

Abstract. Background:. Accumulating evidence have revealed that pretreatment albumin to globulin ratio (AGR) may be a predictor of prognosis among patients with colorectal cancer (CRC). However, these findings are inconsistent. The aim of the present study was to investigate the prognostic value of pretreatment AGR in CRC. Methods:. A systematic meta-analysis was conducted by searching MEDLINE, EMBASE, and Cochrane Library databases. Results:. A total of 9 studies with 7939 patients were finally included. Low pretreatment AGR was associated with worse overall survival (pooled hazard ratio [HR]: 2.07, 95% CI: 1.60–2.67, P 37 U/mL). Conclusion:. The present meta-analysis suggests that low pretreatment AGR was associated with advanced clinicopathological features and worse prognosis, suggesting AGR is a useful prognostic biomarker for CRC patients.